Скачать или смотреть Top 20 Hair Research Studies of 2025

In this video, Dr. Donovan reviews the 20 most influential hair research studies published in the year 2025. This public webinar was conducted on December 29, 2025.


GROUP 1 STUDIES: MINOXIDIL-RELATED STUDIES

Fonseca LPC et al (starts at 5:07). Oral minoxidil 2.5 mg versus 5 mg for male androgenetic alopecia: A double-blind randomized clinical trial. J Am Acad Dermatol. 2026;94(1):316-317.

Bi L et al (starts at 12:19). Whether the transient hair shedding phase exist after minoxidil treatment and does it predict treatment efficacy? A retrospective study in androgenetic alopecia patients. J Dermatolog Treat. 2025;36(1):2480739.

Sanabria B et al (starts at 18:26). Sublingual Minoxidil 5mg versus Oral Minoxidil 5mg for male androgenetic alopecia: A double-blind randomized clinical trial. J Eur Acad Dermatol Venereol. 2025;39:e700-e702.

Kushnir-Grinbaum D et al (starts at 27:06). Continued year-on-year improvement in hair density with systemic minoxidil in women with female pattern hair loss: A case series. J Am Acad Dermatol. 2025;93(1):279-280.



GROUP 2 STUDIES: ANTIANDROGEN-RELATED STUDIES

Singal A et al (starts at 35:00). Exposure to 5-Alpha Reductase Inhibitors and Spironolactone Is Not Associated With Increased Odds of Gynecologic Tumors in a Large Cohort Study of Patients With Alopecia. Int J Dermatol. 2025;64:2131-2133.

Venkatesh T et al (starts at 43:43). Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study. J Am Acad Dermatol. 2025;92(1):163–164.

Sereepanpanich V et al (starts at 47:01). Efficacy and safety of twice- or thrice-weekly dutasteride versus daily finasteride in men with androgenetic alopecia: A randomized, investigator-blinded, active-controlled, parallel-group pilot study. JAAD Int. 2025;23:69-76.





GROUP 3 STUDIES: TELOGEN EFFLUVIUM

Asfour L et al (starts at 55:37). You cannot go bald without first losing your hair: telogen effluvium is a precursor to, prerequisite for and potentially an incitant to common baldness in men. Clin Exp Dermatol. 2025;00:1–6.




GROUP 4 STUDIES: GLP1 RECEPTOR AGONIST- RELATED HAIR LOSS

Burke O et al (starts at 1:04:59). Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol. 2025;92(5):1141-1142.


GROUP 5 STUDIES: ALOPECIA AREATA

Kim SR, Park SH, Koh S-J, Park H (starts at 1:14:49). Association of infantile antibiotic exposure and its changes with pediatric alopecia areata. J Invest Dermatol. 2025;145:188–190. doi:10.1016/j.jid.2024.06.1287.

Hirpara M, Greene R, Chapman M, Albers CG, Mesinkovska N (starts at 1:22:58). Microscopic colitis in alopecia areata: A gut-skin connection beyond the follicle. JAAD International. 2025;23: 55 - 57. doi:10.1016/j.jdin.2025.08.003

Kalil L, Valido K, Peterson D, King B (starts at 1:29:25). Oral minoxidil treatment of alopecia areata. J Am Acad Dermatol. 2025;93(4):1099-1101. doi:10.1016/j.jaad.2025.05.1446

Ogbutor C, Chen L-C, Kalil LL, et al (starts at 1:39:08). Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series. Int J Womens Dermatol. 2025





GROUP 6 STUDIES: SEBORRHEIC DERMATITIS

Meng S, Berna R, Hoffstad O, Takeshita J, Shin D, Chiesa Fuxench ZC, Margolis DJ (starts at 1:47:16). Epithelial Barrier Diseases Among Adult Patients With Seborrheic Dermatitis. JAMA Dermatol. Published online November 5, 2025.





GROUP 7 STUDIES: SCARRING ALOPECIA

LICHEN PLANOPILARIS

Needle C et al (starts at 1:56:24). Efficacy and tolerability of low-dose versus high-dose doxycycline in the management of lymphocytic scarring alopecias. J Am Acad Dermatol. 2025;92(6):1431-1433


FRONTAL FIBROSING ALOPECIA

Wyche J et al (starts at 2:05:14). Odds of developing frontal fibrosing alopecia more closely tied to affluence than race: A retrospective cohort study. J Am Acad Dermatol. 2025;93(3):830-831.

Martin A, Shokrian N, Kelley KJ, Correa da Rosa J, Del-Duca E, Bissonnette R, et al (starts at 2:16:35. Randomized Controlled Trial of the Topical JAK Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia. J Invest Dermatol. 2025;



CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA

Wyche J, Aguh C (starts at 2:24:28). Homeostasis model assessment of insulin resistance enhances detection of insulin resistance in younger patients with central centrifugal cicatricial alopecia. J Am Acad Dermatol. 2025;93(6):1599-1600



FOLLICULITIS DECALVANS

Cova-Martín R et al (starts at 2:31:28). Hair transplantation in folliculitis decalvans: Outcome description in a multicentre series of 11 patients. J Eur Acad Dermatol Venereol. 2025;39:e845-e849


DISSECTING CELLULITIS

Patel D, Thakker S, Olagun-Samuel C, et al (starts at 2:41:30). Long-term cardiovascular morbidity in dissecting cellulitis: A propensity-matched TrinetX cohort study. J Am Acad Dermatol. 2025;93(6):1614-1616.